The (blue label) is a once-weekly maintenance injection primarily used to manage Type 2 diabetes and reduce the risk of major cardiovascular events. Each pen contains 4 mg of semaglutide in a 3 mL solution, designed to deliver exactly four weekly doses of 1 mg . Key Benefits and Uses
Multifactor Quality and Safety Analysis of Semaglutide ... - PMC ozempic 1 mg pen
The fixed 1 mg dose + once-weekly schedule creates a flat peak-to-trough ratio (~1.6). Unlike insulin pens that allow titration, the Ozempic pen enforces a : patient must use the 0.25 mg starter pen (red label) for 4 weeks, then 0.5 mg pen (blue label) for 4 weeks, before receiving the 1 mg pen (green label). This is not a mechanical limitation but a regulatory-prompted dosing lockout to reduce GI side effects. The (blue label) is a once-weekly maintenance injection
| Dose setting | Mean delivered (mg) | CV (%) | Pass/Fail (5% tolerance) | |--------------|--------------------|--------|---------------------------| | 1.0 mg | 0.97–1.03 | <3.5 | Pass | | 0.25 mg (prime) | 0.23–0.27 | <5.0 | N/A (not therapeutic) | - PMC The fixed 1 mg dose +
Semaglutide mimics the action of the natural hormone GLP-1. It works through three primary mechanisms:
